ChromaDex (NASDAQ:CDXC) Lowered to Buy Rating by StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Several other research firms have also weighed in on CDXC. Roth Mkm boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th.

ChromaDex Stock Performance

Shares of ChromaDex stock traded up $0.03 during trading on Friday, reaching $5.51. The company had a trading volume of 332,655 shares, compared to its average volume of 399,378. ChromaDex has a fifty-two week low of $1.36 and a fifty-two week high of $7.97. The firm’s fifty day moving average is $6.29 and its 200-day moving average is $4.24. The company has a market cap of $420.87 million, a price-to-earnings ratio of 551.55 and a beta of 2.15.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. On average, research analysts anticipate that ChromaDex will post 0.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of ChromaDex by 11.1% during the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after buying an additional 33,150 shares during the period. Franklin Resources Inc. bought a new stake in ChromaDex during the 3rd quarter valued at $68,000. Barclays PLC boosted its position in ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after acquiring an additional 53,472 shares during the period. Geode Capital Management LLC grew its stake in shares of ChromaDex by 1.6% in the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock worth $4,197,000 after purchasing an additional 17,963 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of ChromaDex by 100.3% during the third quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock valued at $167,000 after purchasing an additional 22,889 shares during the period. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.